Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceritinib in ALK-Positive NSCLC Previously Treated With Alectinib
NCT02450903Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2015
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ceritinib in non-small cell lung cancer (NSCLC), sponsored by Novartis. Started Aug 2015; status: completed.
02
Drugs
ceritinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02450903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02450903.